Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine (Q45404033)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

14 December 2017

Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine (English)

1 reference

Europe PubMed Central

14 December 2017

1 reference

based on heuristic

inferred from title

15

object named as

Jorma Paavonen

1 reference

Europe PubMed Central

14 December 2017

author name string

Sven-Eric Olsson

1

1 reference

Europe PubMed Central

14 December 2017

Luisa L Villa

2

1 reference

Europe PubMed Central

14 December 2017

Ronaldo L R Costa

3

1 reference

Europe PubMed Central

14 December 2017

Carlos A Petta

4

1 reference

Europe PubMed Central

14 December 2017

Rosires P Andrade

5

1 reference

Europe PubMed Central

14 December 2017

Christian Malm

6

1 reference

Europe PubMed Central

14 December 2017

Ole-Erik Iversen

7

1 reference

Europe PubMed Central

14 December 2017

John Høye

8

1 reference

Europe PubMed Central

14 December 2017

Margareta Steinwall

9

1 reference

Europe PubMed Central

14 December 2017

Grete Riis-Johannessen

10

1 reference

Europe PubMed Central

14 December 2017

Agneta Andersson-Ellstrom

11

1 reference

Europe PubMed Central

14 December 2017

Kristina Elfgren

12

1 reference

Europe PubMed Central

14 December 2017

Geo von Krogh

13

1 reference

Europe PubMed Central

14 December 2017

Matti Lehtinen

14

1 reference

Europe PubMed Central

14 December 2017

Gretchen M Tamms

16

1 reference

Europe PubMed Central

14 December 2017

Katherine Giacoletti

17

1 reference

Europe PubMed Central

14 December 2017

Lisa Lupinacci

18

1 reference

Europe PubMed Central

14 December 2017

Mark T Esser

19

1 reference

Europe PubMed Central

14 December 2017

Scott C Vuocolo

20

1 reference

Europe PubMed Central

14 December 2017

Alfred J Saah

21

1 reference

Europe PubMed Central

14 December 2017

Eliav Barr

22

1 reference

Europe PubMed Central

14 December 2017

language of work or name

0 references

publication date

20 April 2007

1 reference

Europe PubMed Central

14 December 2017

1 reference

Europe PubMed Central

14 December 2017

25

1 reference

Europe PubMed Central

14 December 2017

4931-4939

1 reference

Europe PubMed Central

14 December 2017

26

1 reference

Europe PubMed Central

14 December 2017

The role of human papillomaviruses in anogenital cancers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.049

7 January 2021

High-risk human papillomavirus infection of the genital tract of women with a previous history or current high-grade vulvar intraepithelial neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.049

7 January 2021

A population-based study of squamous cell vaginal cancer: HPV and cofactors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.049

7 January 2021

Role of human papillomavirus in penile cancer, penile intraepithelial squamous cell neoplasias and in genital warts.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.049

7 January 2021

Clinical implications of human papillomavirus in head and neck cancers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.049

7 January 2021

Latent papillomavirus and recurring genital warts

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.049

7 January 2021

High incidence of cervical human papillomavirus infection in women during their first sexual relationship

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.049

7 January 2021

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.049

7 January 2021

Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.049

7 January 2021

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.049

7 January 2021

Immunogenicity of hepatitis B vaccines: implications of immune memory

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.049

7 January 2021

Lifelong protection against hepatitis B: the role of vaccine immunogenicity in immune memory

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.049

7 January 2021

Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.049

7 January 2021

Vaccine induced immunologic memory for hepatitis B surface antigen: implications for policy on booster vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.049

7 January 2021

Anamnestic response to administration of purified non-adsorbed hepatitis B surface antigen in healthy responders to hepatitis B vaccine with long-term non-protective antibody titres

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.049

7 January 2021

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.049

7 January 2021

Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.049

7 January 2021

A controlled trial of a human papillomavirus type 16 vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.049

7 January 2021

A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.049

7 January 2021

Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.049

7 January 2021

Maintenance of B-cell memory by long-lived cells generated from proliferating precursors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.049

7 January 2021

Antigen-specific memory B cell development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.049

7 January 2021

Protective long-term antibody memory by antigen-driven and T help-dependent differentiation of long-lived memory B cells to short-lived plasma cells independent of secondary lymphoid organs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.049

7 January 2021

Maintenance of serum antibody levels

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.049

7 January 2021

Immunogenicity and reactogenicity of a novel vaccine for human papillomavirus 16: a 2-year randomized controlled clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.049

7 January 2021

Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.049

7 January 2021

Postattachment neutralization of papillomaviruses by monoclonal and polyclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.049

7 January 2021

Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.049

7 January 2021

Combined prophylactic and therapeutic cancer vaccine: enhancing CTL responses to HPV16 E2 using a chimeric VLP in HLA-A2 mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.03.049

7 January 2021

Identifiers

10.1016/J.VACCINE.2007.03.049

1 reference

Europe PubMed Central

14 December 2017

1 reference

Europe PubMed Central

14 December 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45404033&oldid=2076639553"